Free Trial

ImmunityBio (IBRX) Competitors

ImmunityBio logo
$3.24 -0.10 (-2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.22 -0.02 (-0.46%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IBRX vs. BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TGTX, TLX, and NUVL

Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

ImmunityBio vs. Its Competitors

Blueprint Medicines (NASDAQ:BPMC) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability.

8.6% of ImmunityBio shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 76.8% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Blueprint Medicines received 526 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 57.14% of users gave ImmunityBio an outperform vote.

CompanyUnderperformOutperform
Blueprint MedicinesOutperform Votes
554
66.99%
Underperform Votes
273
33.01%
ImmunityBioOutperform Votes
28
57.14%
Underperform Votes
21
42.86%

In the previous week, Blueprint Medicines had 20 more articles in the media than ImmunityBio. MarketBeat recorded 27 mentions for Blueprint Medicines and 7 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.60 beat Blueprint Medicines' score of 0.41 indicating that ImmunityBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
10 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImmunityBio
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Blueprint Medicines currently has a consensus target price of $129.35, indicating a potential upside of 1.10%. ImmunityBio has a consensus target price of $12.25, indicating a potential upside of 277.50%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
ImmunityBio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Blueprint Medicines has a net margin of -13.19% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-13.19% -77.49% -20.84%
ImmunityBio -8,016.83%N/A -110.02%

Blueprint Medicines has higher revenue and earnings than ImmunityBio. Blueprint Medicines is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$562.12M14.70-$67.09M-$2.47-51.80
ImmunityBio$31.22M91.73-$583.20M-$0.58-5.59

Summary

Blueprint Medicines and ImmunityBio tied by winning 9 of the 18 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBRX vs. The Competition

MetricImmunityBioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.87B$3.12B$5.60B$8.68B
Dividend YieldN/A1.59%5.27%4.19%
P/E Ratio-3.5433.8027.3520.20
Price / Sales91.73476.96413.76161.05
Price / CashN/A168.6838.2534.64
Price / Book-3.693.507.164.75
Net Income-$583.20M-$72.35M$3.23B$247.80M
7 Day Performance10.75%8.15%3.45%2.78%
1 Month Performance56.76%22.72%12.92%10.13%
1 Year Performance-45.55%-15.93%32.08%15.59%

ImmunityBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBRX
ImmunityBio
2.251 of 5 stars
$3.24
-3.0%
$12.25
+278.1%
-46.5%$2.86B$31.22M-3.52590Gap Up
BPMC
Blueprint Medicines
1.078 of 5 stars
$127.65
+25.9%
$126.63
-0.8%
+23.0%$8.24B$562.12M-118.15640High Trading Volume
ROIV
Roivant Sciences
2.3177 of 5 stars
$11.10
+1.0%
$17.50
+57.7%
+7.5%$7.91B$29.05M-73.90860
RVMD
Revolution Medicines
4.2979 of 5 stars
$41.10
+4.3%
$67.08
+63.2%
+5.3%$7.65B$742K-11.44250
VRNA
Verona Pharma
2.4557 of 5 stars
$83.62
+3.0%
$82.13
-1.8%
+586.0%$6.77B$118.54M-43.4930Trending News
Analyst Forecast
Analyst Revision
BBIO
BridgeBio Pharma
4.6336 of 5 stars
$35.10
+2.5%
$57.09
+62.6%
+44.1%$6.67B$127.42M-12.32400Analyst Forecast
Analyst Revision
Gap Up
ELAN
Elanco Animal Health
1.3302 of 5 stars
$13.29
-1.2%
$15.17
+14.2%
-21.7%$6.59B$4.43B33.169,800Positive News
GRFS
Grifols
3.643 of 5 stars
$8.25
-0.8%
N/A+26.9%$5.65B$7.21B7.0226,300Positive News
TGTX
TG Therapeutics
2.7521 of 5 stars
$35.44
+0.9%
$40.80
+15.1%
+148.0%$5.63B$386.39M-354.79290Positive News
Analyst Revision
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.76
-1.4%
$22.00
+31.3%
N/A$5.57B$783.21M0.00N/APositive News
NUVL
Nuvalent
2.1205 of 5 stars
$76.68
+2.8%
$115.50
+50.6%
-0.7%$5.51BN/A-22.1240Positive News

Related Companies and Tools


This page (NASDAQ:IBRX) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners